Impaired Nicotinamide Adenine Dinucleotide Biosynthesis in the Kidney of Chronic Kidney Disease

Abstract

Chronic kidney disease (CKD) is a global public health problem with high morbidity and mortality. Decreased nicotinamide adenine dinucleotide (NAD+) levels were found to be associated with aging, cancer, and neurodegenerative and metabolic disorders. However, the alteration of renal NAD+ levels and biosynthesis pathways in CKD is less known. In the present study, we aimed to evaluate renal NAD+ levels and tested the expression of key enzymes in three NAD+ biosynthesis pathways in two different types of CKD rat model. CKD rat models were established by 5/6 nephrectomy (5/6 Nx) and feeding with adenine-containing feed, respectively. Renal function was assessed by serum creatinine (Scr) and blood urea nitrogen (BUN). Renal pathology was evaluated by periodic acid-Schiff (PAS) and Masson’s trichrome staining. The expression of key enzymes in three NAD+ biosynthesis pathways was determined and quantified by Western blot analysis. The results showed CKD rat models were successfully established as evidenced by increased Scr and BUN levels, upregulation of neutrophil gelatinase-associated lipocalin (NGAL), glomerular hypertrophy, and renal fibrosis. Renal NAD+ and NADH content were both declined in two CKD rat models, and NAD+ levels were negatively correlated with Scr and BUN levels in CKD rats. Three key enzymes involved in NAD+ biosynthesis were significantly downregulated in the kidney of both of the two CKD models. They were quinolinate phosphoribosyltransferase (QPRT) in the de novo pathway, nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1), and NMNAT3 in the salvage pathway. Moreover, the expression of NAD+-consuming enzymes sirtuin 3 (SIRT3) and CD38 decreased significantly in CKD rats. In conclusion, NAD+ biosynthesis was significantly impaired in CKD, which may attribute to downregulation of QPRT and NMNAT 1/3.

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

“…NAD+/NADH imbalance in DKD manifests as NAD+ decline and NADH overload, which aggravates oxidative stress mediated by ROC in the kidneys and causes mitochondrial dysfunction, energy metabolic disorders and inactivation of various NAD+-dependent enzymes [ 51 ]. In a study, impaired NAD+ synthesis in mice with CKD was associated with decreased expression of key enzymes, including quinolinate phosphoribosyl transferase (QPRT) in the NAD+ de novo synthesis pathway and nicotinamide nucleotide adenylyl transferase 1 (NMNAT1) and NMNAT 3 in the salvage synthesis pathway [ 54 ]. In this study, the expression of NAMN (precursor to the NAD+ de novo synthesis pathway) and niacinamide (NAM, precursor to the salvage synthesis pathway) was increased after EMPA treatment, indicating that these key enzymes may act as targets for EMPA to amend energy metabolism.…”

SIRT6 overexpression retards renal interstitial fibrosis through targeting HIPK2 in chronic kidney disease

“…Since improvement in renal fibrosis can also be seen through further SIRT6 overexpression, we thought it might be a compensatory mechanism. Besides, the level of NAD was declined in the development of CKD, which might also contributed to the defective function of SIRT6 ( Liu et al, 2021 ).…”

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice

“…NAD + metabolism is considered a therapeutic target for kidney disease. 35 , 36 , 56 , 57 Recently, Faivre et al found that impaired NAD + biosynthesis exacerbated acute kidney injury. 36 Our results showed that metabolites related to mitochondrial function changed, such as NAD and taurine, which were well-known antioxidant substrates.…”